Read More

Analysts Eye Summit Therapeutics’ Ivonescimab As Potential Challenger To Merck’s Keytruda in Lung Cancer Treatment

Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in 2024 and a $5 billion deal add to the optimism, signaling potential share price growth ahead.

MRK

Read More

Does Boeing’s Management Overhaul Signal Crucial Turning Point? Analysts Weigh In

Analysts from Benchmark and BofA Securities expressed their views on recent significant management changes and delivery concerns at Boeing. This week, David Calhoun, the CEO of Boeing, revealed the decision to step down along with chairman Larry Kellner in the wake of an investigation by federal authorities into the January incident when a door panel blew out in mid-flight.

AAL

Read More

Prescription Race: Amazon Ramps Up Same-Day Delivery In Major Cities

Amazon (NASDAQ:AMZN) Expands Pharmacy Delivery to New York and Los Angeles: Same-Day Service for Common Prescriptions" - AMZN extends pharmacy delivery to major cities, offering quick access to essential medications like flu treatments and blood pressure management. Expansion plans include over a dozen U.S. cities by year-end, leveraging small-format facilities for efficient stock management and faster delivery options.

AMZN

Read More

Diamondback Energy Shares Climb On Better-Than-Expected Q4 Earnings

Diamondback Energy reported quarterly adjusted earnings of $4.74 per share which beat the analyst consensus estimate of $4.66 by 1.72%. The company reported quarterly sales of $2.23 billion which beat the analyst consensus estimate of $2.17 billion by 2.67% and represents a 9.75% increase over sales of $2.03 billion from the same period last year.

FANG